National Bank of Canada FI Grows Holdings in Kenvue Inc. (NYSE:KVUE)

National Bank of Canada FI increased its holdings in Kenvue Inc. (NYSE:KVUE - Free Report) by 277.5% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 1,215,553 shares of the company's stock after acquiring an additional 893,557 shares during the period. National Bank of Canada FI owned approximately 0.06% of Kenvue worth $25,952,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Grove Bank & Trust raised its stake in shares of Kenvue by 438.4% in the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company's stock valued at $25,000 after acquiring an additional 947 shares during the period. Geneos Wealth Management Inc. purchased a new stake in Kenvue in the fourth quarter valued at approximately $29,000. SRS Capital Advisors Inc. lifted its stake in Kenvue by 67.4% during the fourth quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company's stock worth $30,000 after purchasing an additional 571 shares in the last quarter. Fortitude Family Office LLC boosted its position in shares of Kenvue by 106.6% during the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company's stock worth $32,000 after buying an additional 777 shares during the period. Finally, Versant Capital Management Inc grew its stake in shares of Kenvue by 300.8% in the fourth quarter. Versant Capital Management Inc now owns 1,920 shares of the company's stock valued at $41,000 after buying an additional 1,441 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

Kenvue Stock Down 5.5 %

Shares of NYSE KVUE traded down $1.29 during midday trading on Friday, hitting $22.33. 17,763,957 shares of the company's stock were exchanged, compared to its average volume of 16,812,043. The firm's fifty day simple moving average is $22.59 and its 200-day simple moving average is $22.46. The company has a market cap of $42.68 billion, a PE ratio of 42.14, a P/E/G ratio of 2.62 and a beta of 1.25. Kenvue Inc. has a twelve month low of $17.67 and a twelve month high of $24.46. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69.

Remove Ads

Kenvue (NYSE:KVUE - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, hitting analysts' consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Research analysts predict that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th were issued a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a dividend yield of 3.67%. The ex-dividend date of this dividend was Wednesday, February 12th. Kenvue's payout ratio is 154.72%.

Wall Street Analysts Forecast Growth

KVUE has been the subject of a number of research analyst reports. Deutsche Bank Aktiengesellschaft cut Kenvue from a "buy" rating to a "hold" rating and lowered their target price for the company from $25.00 to $24.00 in a report on Thursday, December 12th. Barclays lifted their price objective on shares of Kenvue from $21.00 to $23.00 and gave the company an "equal weight" rating in a report on Thursday, March 27th. Piper Sandler increased their target price on shares of Kenvue from $24.00 to $27.00 and gave the stock an "overweight" rating in a report on Monday, February 24th. UBS Group decreased their price target on shares of Kenvue from $23.00 to $21.00 and set a "neutral" rating for the company in a research report on Friday, February 7th. Finally, Royal Bank of Canada reaffirmed a "sector perform" rating and set a $24.00 price objective on shares of Kenvue in a research report on Monday, February 3rd. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $24.00.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.